News
Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...
Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
Eli Lilly experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to ...
Eli Lilly stock (NYSE: LLY) stock is showing positive momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results